Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”

Detalles Bibliográficos
Autores principales: Kepka, Lucyna, Socha, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754697/
https://www.ncbi.nlm.nih.gov/pubmed/32603673
http://dx.doi.org/10.1016/j.radonc.2020.06.019
_version_ 1784851257405472768
author Kepka, Lucyna
Socha, Joanna
author_facet Kepka, Lucyna
Socha, Joanna
author_sort Kepka, Lucyna
collection PubMed
description
format Online
Article
Text
id pubmed-9754697
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-97546972022-12-16 Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?” Kepka, Lucyna Socha, Joanna Radiother Oncol Letter to the Editor Elsevier B.V. 2021-01 2020-06-27 /pmc/articles/PMC9754697/ /pubmed/32603673 http://dx.doi.org/10.1016/j.radonc.2020.06.019 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Kepka, Lucyna
Socha, Joanna
Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
title Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
title_full Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
title_fullStr Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
title_full_unstemmed Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
title_short Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
title_sort response to “hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: is split-dose chemotherapy safer than full dose chemotherapy?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754697/
https://www.ncbi.nlm.nih.gov/pubmed/32603673
http://dx.doi.org/10.1016/j.radonc.2020.06.019
work_keys_str_mv AT kepkalucyna responsetohypofractionatedchemoradiotherapyforlocallyadvancednonsmallcelllungcancerissplitdosechemotherapysaferthanfulldosechemotherapy
AT sochajoanna responsetohypofractionatedchemoradiotherapyforlocallyadvancednonsmallcelllungcancerissplitdosechemotherapysaferthanfulldosechemotherapy

Ejemplares similares